OVID Key Statistics, Chart & Performance
The current stock price of OVID is 1.67 USD. In the past month the price increased by 3.09%. In the past year, price increased by 103.49%.
OVID Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About OVID
Company Profile
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Company Info
OVID THERAPEUTICS INC
441 Ninth Avenue, 14Th Floor
New York City NEW YORK 10036 US
CEO: Jeremy M. Levin
Employees: 23
Phone: 12127764381
OVID THERAPEUTICS INC / OVID FAQ
Can you describe the business of OVID THERAPEUTICS INC?
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
What is the stock price of OVID THERAPEUTICS INC today?
The current stock price of OVID is 1.67 USD. The price decreased by -3.47% in the last trading session.
Does OVID stock pay dividends?
OVID does not pay a dividend.
How is the ChartMill rating for OVID THERAPEUTICS INC?
OVID has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting OVID stock to perform?
15 analysts have analysed OVID and the average price target is 4.26 USD. This implies a price increase of 155% is expected in the next year compared to the current price of 1.67.
What is the employee count for OVID stock?
OVID THERAPEUTICS INC (OVID) currently has 23 employees.
OVID Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OVID. When comparing the yearly performance of all stocks, OVID is one of the better performing stocks in the market, outperforming 92.73% of all stocks.
OVID Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OVID. The financial health of OVID is average, but there are quite some concerns on its profitability.
OVID Financial Highlights
Over the last trailing twelve months OVID reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -6.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.9% | ||
| ROE | -81.28% | ||
| Debt/Equity | 0 |
OVID Forecast & Estimates
15 analysts have analysed OVID and the average price target is 4.26 USD. This implies a price increase of 155% is expected in the next year compared to the current price of 1.67.
For the next year, analysts expect an EPS growth of -30.82% and a revenue growth 892.86% for OVID